Profund Advisors LLC Acquires 9,285 Shares of Johnson & Johnson $JNJ

Key Points

• Profund Advisors LLC increased its Johnson & Johnson stake by 25.2% in the fourth quarter, buying 9,285 additional shares and bringing its total holdings to 46,102 shares valued at about $9.54 million.
• Johnson & Johnson reported better-than-expected quarterly results, with EPS of $2.70 and revenue of $24.06 billion, and it also raised its quarterly dividend to $1.34 per share from $1.30.
• Analyst sentiment remains upbeat, with several firms raising price targets and the stock carrying a Moderate Buy consensus target of $253.04, while the shares recently traded around $228.80.

Profund Advisors LLC raised its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 25.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 46,102 shares of the company's stock after buying an additional 9,285 shares during the period. Profund Advisors LLC's holdings in Johnson & Johnson were worth $9,541,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently made changes to their positions in JNJ. Brighton Jones LLC increased its holdings in Johnson & Johnson by 13.9% during the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company's stock worth $7,502,000 after purchasing an additional 6,332 shares in the last quarter. United Bank lifted its holdings in shares of Johnson & Johnson by 110.7% in the first quarter. United Bank now owns 9,279 shares of the company's stock valued at $1,539,000 after purchasing an additional 4,876 shares in the last quarter. Sivia Capital Partners LLC boosted its position in shares of Johnson & Johnson by 13.4% during the second quarter. Sivia Capital Partners LLC now owns 5,863 shares of the company's stock valued at $896,000 after buying an additional 692 shares during the last quarter. Wealth Group Ltd. boosted its position in shares of Johnson & Johnson by 12.8% during the second quarter. Wealth Group Ltd. now owns 1,482 shares of the company's stock valued at $226,000 after buying an additional 168 shares during the last quarter. Finally, Schnieders Capital Management LLC. grew its holdings in Johnson & Johnson by 9.8% during the second quarter. Schnieders Capital Management LLC. now owns 73,680 shares of the company's stock worth $11,255,000 after buying an additional 6,584 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. Raymond James Financial raised their price objective on Johnson & Johnson from $237.00 to $258.00 and gave the company an "outperform" rating in a research note on Wednesday, April 15th. The Goldman Sachs Group upped their target price on shares of Johnson & Johnson from $265.00 to $275.00 and gave the stock a "buy" rating in a research note on Wednesday, April 15th. Scotiabank reissued an "outperform" rating on shares of Johnson & Johnson in a research report on Thursday, January 22nd. TD Cowen initiated coverage on shares of Johnson & Johnson in a report on Wednesday, April 8th. They set a "buy" rating and a $250.00 price target on the stock. Finally, Wells Fargo & Company increased their price objective on shares of Johnson & Johnson from $240.00 to $263.00 and gave the company an "overweight" rating in a research note on Wednesday, April 15th. Twenty analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $253.04.

Johnson & Johnson Trading Up 0.9%

NYSE JNJ opened at $228.80 on Tuesday. The business's fifty day moving average is $234.91 and its 200-day moving average is $222.31. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.03 and a quick ratio of 0.77. The stock has a market capitalization of $550.76 billion, a price-to-earnings ratio of 26.45, a PEG ratio of 2.22 and a beta of 0.27. Johnson & Johnson has a one year low of $149.04 and a one year high of $251.71.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Tuesday, April 14th. The company reported $2.70 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.68 by $0.02. The business had revenue of $24.06 billion during the quarter, compared to the consensus estimate of $23.60 billion. Johnson & Johnson had a net margin of 21.83% and a return on equity of 32.60%. The firm's quarterly revenue was up 9.9% compared to the same quarter last year. During the same quarter last year, the company posted $2.77 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. Equities research analysts predict that Johnson & Johnson will post 11.57 EPS for the current year.

Johnson & Johnson Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 9th. Investors of record on Tuesday, May 26th will be issued a $1.34 dividend. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.30. The ex-dividend date of this dividend is Tuesday, May 26th. This represents a $5.36 annualized dividend and a yield of 2.3%. Johnson & Johnson's payout ratio is 60.12%.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Leerink Partners upgraded Johnson & Johnson to Outperform from Market Perform and raised its price target to $265, citing strong new-drug momentum and improved growth prospects. Article: Is Johnson & Johnson (JNJ) One of the Best “Dogs of the Dow” Stocks to Buy for the Rest of 2026?
• Positive Sentiment: J&J’s oncology pipeline received attention after the company presented encouraging early/Phase 2 data for JNJ-1900 (NBTXR3) in inoperable lung cancer, reinforcing the company’s cancer-treatment growth story. Article: Johnson & Johnson Lung Cancer Data Adds Dimension To Oncology Valuation Story
• Positive Sentiment: Multiple articles highlighted Johnson & Johnson as a strong dividend and “Dogs of the Dow” name, which supports the stock’s defensive appeal for income-focused investors. Article: Why Johnson & Johnson (JNJ) is a Great Dividend Stock Right Now
• Neutral Sentiment: Nanobiotix also said J&J presented Part 1 data from the CONVERGE study, adding more visibility to the company’s oncology collaboration, though the market impact appears limited so far. Article: Nanobiotix Reports Promising Phase 2 Data for NBTXR3 in Stage 3 Inoperable Lung Cancer
• Negative Sentiment: The U.S. Supreme Court declined to hear a challenge to the Medicare drug-price negotiation program, leaving intact a policy that could continue to pressure pricing for Johnson & Johnson’s pharmaceutical business. Article: Supreme Court Rejects Drugmakers’ Challenge to Medicare Price Negotiation Program

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Timothy Schmid sold 1,322 shares of the company's stock in a transaction dated Friday, February 20th. The shares were sold at an average price of $245.66, for a total transaction of $324,762.52. Following the sale, the executive vice president directly owned 25,447 shares of the company's stock, valued at $6,251,310.02. This represents a 4.94% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 0.16% of the company's stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.